Literature DB >> 25295709

Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial.

Yahya Shehabi1, Martin Sterba, Peter Maxwell Garrett, Kanaka Sundaram Rachakonda, Dianne Stephens, Peter Harrigan, Alison Walker, Michael J Bailey, Bronwyn Johnson, David Millis, Geoff Ding, Sandra Peake, Helen Wong, Jane Thomas, Kate Smith, Loretta Forbes, Miranda Hardie, Sharon Micallef, John F Fraser.   

Abstract

RATIONALE: The role of procalcitonin (PCT), a widely used sepsis biomarker, in critically ill patients with sepsis is undetermined.
OBJECTIVES: To investigate the effect of a low PCT cut-off on antibiotic prescription and to describe the relationships between PCT plasma concentration and sepsis severity and mortality.
METHODS: This was a multicenter (11 Australian intensive care units [ICUs]), prospective, single-blind, randomized controlled trial involving 400 patients with suspected bacterial infection/sepsis and expected to receive antibiotics and stay in ICU longer than 24 hours. The primary outcome was the cumulative number of antibiotics treatment days at Day 28.
MEASUREMENTS AND MAIN RESULTS: PCT was measured daily while in the ICU. A PCT algorithm, including 0.1 ng/ml cut-off, determined antibiotic cessation. Published guidelines and antimicrobial stewardship were used in all patients. Primary analysis included 196 (PCT) versus 198 standard care patients. Ninety-three patients in each group had septic shock. The overall median (interquartile range) number of antibiotic treatment days were 9 (6-21) versus 11 (6-22), P = 0.58; in patients with positive pulmonary culture, 11 (7-27) versus 15 (8-27), P = 0.33; and in patients with septic shock, 9 (6-22) versus 11 (6-24), P = 0.64; with an overall 90-day all-cause mortality of 35 (18%) versus 31 (16%), P = 0.54 in the PCT versus standard care, respectively. Using logistic regression, adjusted for age, ventilation status, and positive culture, the decline rate in log(PCT) over the first 72 hours independently predicted hospital and 90-day mortality (odds ratio [95% confidence interval], 2.76 [1.10-6.96], P = 0.03; 3.20 [1.30-7.89], P = 0.01, respectively).
CONCLUSIONS: In critically ill adults with undifferentiated infections, a PCT algorithm including 0.1 ng/ml cut-off did not achieve 25% reduction in duration of antibiotic treatment. Clinical trial registered with http://www.anzctr.org.au (ACTRN12610000809033).

Entities:  

Keywords:  critically ill; infection; intensive care; procalcitonin; sepsis

Mesh:

Substances:

Year:  2014        PMID: 25295709     DOI: 10.1164/rccm.201408-1483OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  55 in total

1.  What's new with biomarker-driven clinical strategy in sepsis and circulatory failure?

Authors:  Armand Mekontso Dessap; Lorraine B Ware; Lila Bouadma
Journal:  Intensive Care Med       Date:  2015-09-21       Impact factor: 17.440

2.  More challenges around sepsis: definitions and diagnosis.

Authors:  Emma Joynes
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

Review 3.  Emerging infection and sepsis biomarkers: will they change current therapies?

Authors:  Lauren Jacobs; Hector R Wong
Journal:  Expert Rev Anti Infect Ther       Date:  2016-08-17       Impact factor: 5.091

Review 4.  Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock.

Authors:  Brenda Ng Andriolo; Regis B Andriolo; Reinaldo Salomão; Álvaro N Atallah
Journal:  Cochrane Database Syst Rev       Date:  2017-01-18

Review 5.  AME evidence series 001-The Society for Translational Medicine: clinical practice guidelines for diagnosis and early identification of sepsis in the hospital.

Authors:  Zhongheng Zhang; Nathan J Smischney; Haibo Zhang; Sven Van Poucke; Panagiotis Tsirigotis; Jordi Rello; Patrick M Honore; Win Sen Kuan; Juliet June Ray; Jiancang Zhou; You Shang; Yuetian Yu; Christian Jung; Chiara Robba; Fabio Silvio Taccone; Pietro Caironi; David Grimaldi; Stefan Hofer; George Dimopoulos; Marc Leone; Sang-Bum Hong; Mabrouk Bahloul; Laurent Argaud; Won Young Kim; Herbert D Spapen; Jose Rodolfo Rocco
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

6.  Antibiotic stewardship in the intensive care unit: tools for de-escalation from the American Thoracic Society Meeting 2016.

Authors:  Kevan Akrami; Daniel A Sweeney; Atul Malhotra
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

7.  Diagnosis of Louse-Borne Relapsing Fever despite Negative Microscopy in Two Asylum Seekers from Eastern Africa.

Authors:  Spinello Antinori; Cristina Tonello; Sophie Edouard; Carlo Parravicini; Daniela Gastaldi; Romualdo Grande; Laura Milazzo; Davide Ricaboni; Florence Fenollar; Didier Raoult; Mario Corbellino; Oleg Mediannikov
Journal:  Am J Trop Med Hyg       Date:  2017-09-21       Impact factor: 2.345

8.  Impact of Pharmacist-Led Procalcitonin-Guided Antibiotic Therapy in Critically Ill Patients With Pneumonia.

Authors:  Bibidh Subedi; Patricia Louzon; Kristie Zappas; Wilfred Onyia; Kevin DeBoer
Journal:  Hosp Pharm       Date:  2019-03-25

9.  How Can We Optimize Antibiotic Use in the PICU?

Authors:  Kathleen Chiotos; Jeffrey S Gerber; Adam S Himebauch
Journal:  Pediatr Crit Care Med       Date:  2017-09       Impact factor: 3.624

10.  Effect of Procalcitonin Testing on Health-care Utilization and Costs in Critically Ill Patients in the United States.

Authors:  Robert A Balk; Sameer S Kadri; Zhun Cao; Scott B Robinson; Craig Lipkin; Samuel A Bozzette
Journal:  Chest       Date:  2016-08-25       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.